Long-Term Results Confirm Subcutaneous Trastuzumab ’s Efficacy in HER2+ Breast Cancer

The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.

Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news